Apyx Medical (APYX) Projected to Post Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $10.78 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $19.16 million for the quarter, compared to analysts’ expectations of $19.12 million. Apyx Medical had a negative return on equity of 114.95% and a negative net margin of 21.22%. On average, analysts expect Apyx Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Apyx Medical Stock Performance

APYX traded down $0.04 during trading on Tuesday, hitting $2.82. The stock had a trading volume of 137,601 shares, compared to its average volume of 137,318. The firm has a market capitalization of $117.75 million, a P/E ratio of -10.48 and a beta of 1.35. The company’s 50-day moving average price is $3.66 and its 200 day moving average price is $3.70. The company has a debt-to-equity ratio of 2.35, a quick ratio of 4.26 and a current ratio of 5.00. Apyx Medical has a twelve month low of $1.04 and a twelve month high of $4.50.

Analysts Set New Price Targets

Several brokerages have recently weighed in on APYX. BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th. Craig Hallum increased their target price on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Finally, Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Apyx Medical has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Institutional Investors Weigh In On Apyx Medical

Several hedge funds have recently modified their holdings of APYX. Citadel Advisors LLC purchased a new stake in shares of Apyx Medical in the third quarter valued at $28,000. Hudson Bay Capital Management LP acquired a new stake in Apyx Medical during the 4th quarter worth about $73,000. Osaic Holdings Inc. acquired a new position in shares of Apyx Medical in the 2nd quarter valued at about $50,000. Franklin Resources Inc. acquired a new stake in shares of Apyx Medical during the third quarter worth approximately $59,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Apyx Medical during the fourth quarter valued at approximately $111,000. 55.33% of the stock is owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.